Fresenius USA Marketing, Inc.
$1.6M 10,547 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Myriad Genetic Laboratories, Inc.
Myriad Genetic Laboratories, Inc. reported $1,567,341.75 across General Payments, Research, and Ownership to 11,970 physicians and teaching hospitals across 12,020 transactions.
- $1.6M
- All-tracks total
- 12,020
- Transactions
- 11,970
- Recipients
- +$52.2K
- General Payments vs PY2023
Myriad Genetic Laboratories, Inc. reported $1,567,341.75 across all CMS Open Payments tracks (General + Research + Ownership) to 11,970 physicians and teaching hospitals in Program Year 2024 - ranking #514 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,362,281.30, averaging $130.94 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer myriad-genetic-laboratories-inc Myriad Genetic Laboratories, Inc.
$1.6M · #514/1,925 · 0.0% industry · PY2024
- TOT $1.6M
- RANK #514
- SHARE 0.0%
- TXN 12,020
- RCP 11,970
- CAT 7
- GEN $1.4M
- ΔGEN +$52.2K
- TOP1 32.9%
- PY 2024
Volume peers
Nearest volume peer: Fresenius USA Marketing, Inc. ($1.6M)
Myriad Genetic Laboratories, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Myriad Genetic Laboratories, Inc.'s CMS-reported General Payments increased by $52.2K (+4.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MYRIAD GENETIC LABORATORIES, INC.PY2023: MYRIAD GENETIC LABORATORIES, INC.PY2024: Myriad Genetic Laboratories, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,310,096.43
- PY2024
- $1,362,281.30
What the Data Shows for Myriad Genetic Laboratories, Inc.
In Program Year 2024, Myriad Genetic Laboratories, Inc. reported $1,567,341.75 in payments to 11,970 physicians and teaching hospitals across 12,020 individual transactions, an average of $130.39 per transaction and $130.94 per recipient. That total places Myriad Genetic Laboratories, Inc. at rank #514 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 7 general-payment categories charted below, "Royalty or License" is the largest at $560.6K across 8 transactions, 41.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 7 types of general payments, Myriad Genetic Laboratories, Inc.'s largest category was "Royalty or License" at $560.6K - 41.2% of General Payments.
Myriad Genetic Laboratories, Inc. reports 7 general-payment categories - the top three are Royalty or License (41.2%), Food and Beverage (25.5%), and Honoraria (15.8%). The remaining 4 categories make up 17.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Myriad Genetic Laboratories, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $560.6K | 8 | 41.2% |
| Food and Beverage | $347.4K | 11,487 | 25.5% |
| Honoraria | $215.8K | 187 | 15.8% |
| Consulting Fee | $213.4K | 174 | 15.7% |
| Travel and Lodging | $15.0K | 111 | 1.1% |
| Grant | $8.5K | 2 | 0.6% |
| Space Rental or Facility Fees | $1.5K | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $717,986.91 (52.7%) of $1,362,281.30 in this company's General Payments records across 5,685 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Myriad Genetic Laboratories, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Childrens Hospital Corporation
$447,519.51 across 4 reported transactions
- 2
Ut Md Anderson Cancer Center
$113,129.63 across 4 reported transactions
- 3
Adam M Brufsky
$65,287.52 across 54 reported transactions
- 4
Devesh Pandya
$46,211.43 across 54 reported transactions
- 5
Alfredo Santillan Gomez
$45,838.82 across 39 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Myriad Genetic Laboratories, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Myriad Genetic Laboratories, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Myriad Genetic Laboratories, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Krystal Biotech Inc
$1.6M 1,118 recipients
Compare payment profiles
Integrity Implants Inc. dba Accelus
$1.6M 1,045 recipients
Compare payment profiles
Zevra Therapeutics Inc
$1.5M 25 recipients
Compare payment profiles
Veloxis Pharmaceuticals, Inc.
$1.6M 766 recipients
Compare payment profiles
Valneva Austria GMBH
$1.6M 1 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.